ZETA Study


Vandetanib in patients with locally advanced or metastatic medullary thyroid cancer: a randomized, double-blind phase III trial

Tyrosine Kinase inhibitors are indicated in patients with a significant MTC tumor burden, symptomatic or progressive disease according to the RECIST (Response Evaluation Criteria in Solid Tumors) assessment criteria.

Cabozantinib, another TKI was also efficacious in MTC (EXAM study)

Reference

Wells SA Jr, Robinson BG, Gagel RF, Dralle H, Fagin JA, Santoro M, Baudin E, Elisei R, Jarzab B, Vasselli JR, Read J, Langmuir P, Ryan AJ, Schlumberger MJ. Vandetanib in patients with locally advanced or metastatic medullary thyroid cancer: a randomized, double-blind phase III trial. J Clin Oncol. 2012 Jan 10;30(2):134-41. doi: 10.1200/JCO.2011.35.5040. Epub 2011 Oct 24. Erratum in: J Clin Oncol. 2013 Aug 20;31(24):3049.

>